Navigation Links
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/27/2008

Extensive Clinical Development Program Investigating Golimumab in the

Treatment of These Diseases Serves as Basis for the Application

HORSHAM, Pa., June 27 /PRNewswire/ -- Centocor, Inc. announced today that a Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Golimumab, Centocor's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also being studied as an intravenous (IV) infusion therapy. In February 2008, Centocor submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting the approval of golimumab as a monthly subcutaneous treatment for the same indications.

"This submission marks a major milestone in the clinical development program of golimumab, and we look forward to working with the FDA to bring golimumab to market," said Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "We remain focused on our commitment to innovation in the field of biomedicines, to addressing the ongoing needs of patients living with these debilitating diseases and to physicians in need of additional therapeutic options to effectively treat their patients."

Five pivotal Phase 3 trials support the BLA, which include the GOlimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of Early onset (GO-BEFORE) study; the GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD) study; and A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Human Anti-TNF-alpha Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNF-alph
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
3. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
4. Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval
5. Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
6. Phyhealth Submits HMO Applications with Required Federal and State Agencies
7. Takeda submits new drug application for alogliptin (syr-322) in the US
8. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
9. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
10. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
11. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration has ... of using beard hair to fill in balding areas ... has now become an absolute option for giving patients the best ... believe that beard to scalp hair transplant can be a patients ... as dense as we would like it,” says Dr. Parsa Mohebi. ...
(Date:3/31/2015)... 2015 The American College of Traditional ... for April will include interesting workshops, lectures and more. ... 9-11 a.m. April 6, ACTCM welcomes the newest cohort. ... the Pioneer Square Campus located at 555 DeHaro St. ... April 14, Students will be updated on the upcoming ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address ... University’s Commencement ceremony on May 9, 2015 and ... recognition of her eminent career as a nurse, public ... caregiver and senior staff nurse at Brigham and Women’s ... leadership roles, including President of the American Nurses Association ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Simeon Boyd, ... a nearly $4 million, five-year grant from the National ... team of physicians and scientists from more than 10 ... including Australia, Brazil, Bulgaria, Germany, Hungary, Italy and the ... the bony plates of the skull in infants. , ...
(Date:3/31/2015)... Medical DNA Labs, LLC, An Affiliate ... for Laboratory Accreditation by COLA, a national healthcare accreditation ... apply rigid standards of quality in day-to-day operations, demonstrate ... pass a rigorous on-site laboratory survey. Medical DNA ... of a long-term commitment to provide quality service to ...
Breaking Medicine News(10 mins):Health News:Is Beard to Scalp Hair Transplant the Future? 2Health News:ACTCM Announces April Event Schedule 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 2Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 3Health News:Local Medical DNA Labs, LLC. Recognized for Quality Laboratory Services 2
... it is not. Yet its,success is none-the-less impressive. ... both worldwide and in the,U.S. since the turn ... for virtual,reality in surgery, medical education, therapy and ... Virtual Reality Market in the US Healthcare,Sector: Markets ...
... Oct. 19 How far can a bright, ... for one super smile could take YOU,all the ... at the People,s,Choice Awards. Listen to this ... journalists can access video, audio, text, graphics and,photos ...
... to fumes at home less likely to pass exams, research ... is secondhand smoke a threat to teen health, it can ... , Researchers at Temple University found that 16- and 18-year-olds ... likely to pass standardized tests than their peers. , They ...
... With safety issues making,headlines, pharmaceutical and ... Organizations are relying on their quality function,to ... Proper,staffing of quality roles is just one ... study by pharmaceutical benchmarking leader Best,Practices, LLC ...
... Single-Payer ... Healthcare, ... thanks Al Gore for,his forceful new words in support of the ... and that is,succeeding in nearly every other industrialized democracy. The ...
... MENTOR, Ohio, Oct. 19 STERIS Corporation,(NYSE: ... its fiscal 2008 second,quarter earnings release before the ... conference call at 10:00 a.m. Eastern time. The ... at http://www.steris-ir.com or via phone,by dialing ...
Cached Medicine News:Health News:Virtual Reality Technology Finds Ready and Willing Market in Healthcare 2Health News:Secondhand Smoke Hurts Kids' Grades 2Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:National Nurses Movement Lauds Al Gore for Leadership on Single-Payer Healthcare 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call 3
(Date:3/31/2015)... March 31, 2015  Oxis International, Inc. (OXIS) (OXI.PA) ... and commercialization, announced today Oxis CEO Tony Cataldo ... Oxis common shares on the Euronext exchange. Oxis shares ... symbol OXIS.   Oxis Chairman and CEO ... move forward with its strategies launched in 2014 and ...
(Date:3/31/2015)... , March 31, 2015 Biorasi ... announced a strategic partnership with Medidata , ... clinical research in life sciences. Offering therapeutic expertise ... has deployed Medidata,s electronic data capture (EDC), management ... Phase I through IV global clinical trial business. ...
(Date:3/31/2015)... SAN DIEGO , March 31, 2015 /PRNewswire/ ... of biopharmaceutical contract development and manufacturing services, ... more top pharmaceutical companies to its growing ... cGMP-produced crystal-based drug products using Althea,s ... additional companies, a total of 4 out ...
Breaking Medicine Technology:Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4Althea's New Drug Formulation Technology Gains Attention from Two More Top Pharmaceutical Companies 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... on-board capacity of 57 assays ... 146 tests, the CX1000 PRO ... so you can maximize your ... workload. The CX1000 PRO creates ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: